好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

A Telemedicine Platform to Increase Access to Migraine Care in Men
Headache
P8 - Poster Session 8 (11:45 AM-12:45 PM)
2-009
To describe differences in access to migraine care between men and women prior to joining a telemedicine platform.
Migraine is three times more prevalent in women than men, and has been “feminized” due to this sex asymmetry, which may contribute to delayed care in men. Asynchronous telemedicine as an anonymized care option may reduce stigma, resulting in increased access to quality migraine care in men.
This study assessed patients who self-enrolled in a direct-to-consumer migraine telemedicine platform, Cove. The platform provides patients access to asynchronous evidence-based consultation, ongoing messaging, and e-pharmacy. Data from patients completing the comprehensive headache-focused intake, including demographics, treatment history, clinical assessments, and healthcare resource use were compared between males and females. Statistical differences between groups were assessed using chi-square and Kruskal-Wallis tests.

Data from 10,151 patients were analyzed (median age 38 years, 13% male). At intake, male and female patients reported the same monthly headache frequency (median: 10 days, p=.09) and similar median intensity (male 7 vs. female 8 on 10-point scale, p=.07). 

Males were less likely than females to have sought migraine care from a primary care physician (68% vs. 77%, p<.01) or neurologist (33% vs. 39%, p<.01) prior to joining the platform. In addition, a lower proportion of males compared to females had received acute (39% vs. 44%, p<.01) and preventive (15% vs. 20%, p<.01) medications in the 6 months before intake.

After joining the telemedicine platform, all patients had increased access to migraine treatment; 88% of males (126% increase) and 92% of females (109% increase) received acute medications and 49% of males (227% increase) and 53% of females (165% increase) received preventive medications.  
Telemedicine platforms may contribute to increased access to evidence-based migraine treatment for men. Future studies should assess factors specific to telemedicine that contribute to increased access to underserved populations.
Authors/Disclosures
Sara C. Crystal, MD (NY Headache Center)
PRESENTER 		Dr. Crystal has received personal compensation for serving as an employee of Thirty Madison. Dr. Crystal has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biohaven. Dr. Crystal has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Allergan.
Alexander A. Mauskop, MD, FAAN (New York Headache Center) Dr. Mauskop has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Allergan. Dr. Mauskop has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Eli Lily. Dr. Mauskop has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Lundbeck. Dr. Mauskop has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biohaven. Dr. Mauskop has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Amgen. Dr. Mauskop has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Teva. Dr. Mauskop has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Allergan.
Alan M. Rapoport, MD, FAAN Dr. Rapoport has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for AbbVie, Amgen, Biohaven, Cala Health, Satsuma, Teva Pharmaceutical Industries, Theranica, Xoc and Zosano. Dr. Rapoport has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for AbbVie, Amgen, Biohaven, Lundbeck and Teva Pharmaceutical Industries. Dr. Rapoport has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurology Reviews.
Robert Cowan, MD, FAAN (Stanford Neurosciences Health Center) Dr. Cowan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Lundbeck. Dr. Cowan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Teva. Dr. Cowan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Abbvie. Dr. Cowan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lilly. Dr. Cowan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biohaven. Dr. Cowan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for lundbeck. Dr. Cowan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for biohavenn. Dr. Cowan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbviie. Dr. Cowan has stock in Percept. Dr. Cowan has received intellectual property interests from a discovery or technology relating to health care. Dr. Cowan has received intellectual property interests from a discovery or technology relating to health care. Dr. Cowan has received publishing royalties from a publication relating to health care.
No disclosure on file
Jessica Kiarashi, MD (UT Southwestern Medical Center) Dr. Kiarashi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for COVE.
No disclosure on file
Adam B. Cohen, MD (Massachusetts General Hospital) Dr. Cohen has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Thirty Madison. Dr. Cohen has received stock or an ownership interest from Thirty Madison.
No disclosure on file